Alatrofloxacin Mesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524161

CAS#: 146961-77-5 (mesylate)

Description: Alatrofloxacin Mesylate is the parental prodrug of Trovafloxacin, a broad-spectrum antibiotic.


Chemical Structure

img
Alatrofloxacin Mesylate
CAS# 146961-77-5 (mesylate)

Theoretical Analysis

MedKoo Cat#: 524161
Name: Alatrofloxacin Mesylate
CAS#: 146961-77-5 (mesylate)
Chemical Formula: C27H29F3N6O8S
Exact Mass: 0.00
Molecular Weight: 654.610
Elemental Analysis: C, 49.54; H, 4.47; F, 8.71; N, 12.84; O, 19.55; S, 4.90

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 146961-77-5 (mesylate)   146961-76-4 (free base)   157605-25-9 (mesylate)    

Synonym: Alatrofloxacin mesylate; CP 116,517; CP 116517; CP-116,517; CP-116517;

IUPAC/Chemical Name: 7-[(1S,5R)-6-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid;methanesulfonic acid

InChi Key: CYETUYYEVKNSHZ-RSUMCGCKSA-N

InChi Code: InChI=1S/C26H25F3N6O5.CH4O3S/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28;1-5(2,3)4/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40);1H3,(H,2,3,4)/t10-,11-,14-,15+,20?;/m0./s1

SMILES Code: O=C(C1=CN(C2=CC=C(F)C=C2F)C3=C(C=C(F)C(N4C[C@@]5([H])C(NC([C@@H](NC([C@@H](N)C)=O)C)=O)[C@@]5([H])C4)=N3)C1=O)O.CS(=O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 654.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mukherjee J. Post-approval translational research itself has diverse ethics. Am J Bioeth. 2010 Aug;10(8):43-4. doi: 10.1080/15265161.2010.496525. PubMed PMID: 20694908.

2: Hsiao CJ, Younis H, Boelsterli UA. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem Biol Interact. 2010 Oct 6;188(1):204-13. doi: 10.1016/j.cbi.2010.07.017. Epub 2010 Jul 23. PubMed PMID: 20655887.

3: Annas GJ. Globalized clinical trials and informed consent. N Engl J Med. 2009 May 14;360(20):2050-3. doi: 10.1056/NEJMp0901474. PubMed PMID: 19439740.

4: Ezeome ER, Simon C. Ethical problems in conducting research in acute epidemics: the Pfizer meningitis study in Nigeria as an illustration. Dev World Bioeth. 2010 Apr;10(1):1-10. doi: 10.1111/j.1471-8847.2008.00239.x. Epub 2008 Jul 28. PubMed PMID: 18665846.

5: Jegede AS. Understanding informed consent for participation in international health research. Dev World Bioeth. 2009 Aug;9(2):81-7. doi: 10.1111/j.1471-8847.2008.00238.x. Epub 2008 Jul 15. PubMed PMID: 18637943.

6: Loewenberg S. Drug company trials come under increasing scrutiny. Lancet. 2008 Jan 19;371(9608):191-2. PubMed PMID: 18217230.

7: Aagaard L, Soendergaard B, Stenver DI, Hansen EH. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector? Br J Clin Pharmacol. 2008 Mar;65(3):364-76. Epub 2007 Oct 24. PubMed PMID: 17961195; PubMed Central PMCID: PMC2291241.

8: Willyard C. Pfizer lawsuit spotlights ethics of developing world clinical trials. Nat Med. 2007 Jul;13(7):763. Epub 2007 Jun 29. PubMed PMID: 17618250.

9: Lenzer J. Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests. BMJ. 2006 May 27;332(7552):1233. PubMed PMID: 16735322; PubMed Central PMCID: PMC1471980.

10: Starr JA, Ragucci KR. Thrombocytopenia associated with intravenous ciprofloxacin. Pharmacotherapy. 2005 Jul;25(7):1030-4. PubMed PMID: 16006282.

11: Hall IH, Schwab UE, Ward ES, Ives TJ. Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes. Biomed Pharmacother. 2003 Oct;57(8):359-65. PubMed PMID: 14568230.

12: Lode H, Grossman C, Choudhri S, Haverstock D, McGivern J, Herman-Gnjidic Z, Church D. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med. 2003 Oct;97(10):1134-42. PubMed PMID: 14561021.

13: Raufu A. Nigerians in drug trial take their case to US court. BMJ. 2003 Apr 26;326(7395):899. PubMed PMID: 12714459; PubMed Central PMCID: PMC1125820.

14: Nakamura T, Fukuda H, Morita Y, Soumi K, Kawamura Y. Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system. J Toxicol Sci. 2003 Feb;28(1):35-45. PubMed PMID: 12696183.

15: Fry DE, Schermer CR. The consequences of suppression of anaerobic bacteria. Surg Infect (Larchmt). 2000;1(1):49-56. Review. PubMed PMID: 12594909.

16: Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew DP. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002 May;46(5):1503-9. PubMed PMID: 11959588; PubMed Central PMCID: PMC127155.

17: Brook I, Elliott TB, Pryor HI 2nd, Sautter TE, Gnade BT, Thakar JH, Knudson GB. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001 Dec;18(6):559-62. PubMed PMID: 11738344.

18: Ready T. Pfizer in "unethical" trial suit. Nat Med. 2001 Oct;7(10):1077. PubMed PMID: 11590414.

19: Mitropoulos FA, Angood PB, Rabinovici R. Trovafloxacin-associated leukopenia. Ann Pharmacother. 2001 Jan;35(1):41-4. PubMed PMID: 11197584.

20: Melvani S, Speed BR. Alatrofloxacin-induced seizures during slow intravenous infusion. Ann Pharmacother. 2000 Sep;34(9):1017-9. PubMed PMID: 10981247.